Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.

Lindsay Rein,Karel Calero,Ronak Shah, Charles Ojielo,Kristin M. Hudock, Saba Lodhi,Farid Sadaka,Shashi Bellam,Christopher Palma,David N. Hager,Jeannie Daniel,Richard Schaub,Kevin O'Hayer,Nicole M. Theodoropoulos

Critical care medicine（2022）

引用 13|浏览16

暂无评分

关键词

COVID-19,Janus kinase inhibitors,randomized controlled trial,respiration,artificial,respiratory distress syndrome,severe acute respiratory syndrome coronavirus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要